Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not all subjects respond, and the duration of response is limited. Our aim was to determine whether two courses of teplizumab, an Fc receptor–nonbinding anti-CD3 monoclonal antibody, reduces the decline in C-peptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Herold, Kevan C., Gitelman, Stephen E., Ehlers, Mario R., Gottlieb, Peter A., Greenbaum, Carla J., Hagopian, William, Boyle, Karen D., Keyes-Elstein, Lynette, Aggarwal, Sudeepta, Phippard, Deborah, Sayre, Peter H., McNamara, James, Bluestone, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806618/
https://www.ncbi.nlm.nih.gov/pubmed/23835333
http://dx.doi.org/10.2337/db13-0345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806618/
https://www.ncbi.nlm.nih.gov/pubmed/23835333
http://dx.doi.org/10.2337/db13-0345

Ejemplares similares